Financial conflicts of interest among authors of clinical practice guideline for headache disorders in Japan.
Clinical practice guideline
Conflicts of interest
Ethics
Evidence-based medicine
Health policy
Journal
BMC medical ethics
ISSN: 1472-6939
Titre abrégé: BMC Med Ethics
Pays: England
ID NLM: 101088680
Informations de publication
Date de publication:
29 Oct 2024
29 Oct 2024
Historique:
received:
17
04
2024
accepted:
24
10
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
epublish
Résumé
Financial relationships between clinical guideline authors and pharmaceutical companies introduce conflicts of interest (COI), potentially biasing guideline recommendations. Thus, proper management of COI is paramount for clinical guideline authors. Nevertheless, little is known about COI among neurology clinical guideline authors. This study aimed to evaluate the financial relationships between pharmaceutical companies and authors of Clinical Practice Guideline for Headache Disorders (CPGHD) in Japan. This is a retrospective analysis of 2016-2020 personal payments data disclosed by all pharmaceutical companies affiliated with the Japan Pharmaceutical Manufacturers Association. We examined amounts and fraction of personal payments to all 57 CPGHD authors and all neurologists board-certified by the Japanese Society of Neurology. Payment data was descriptively analyzed at individual author level. Among 57 CPGHD authors, 56 (98.3%) received personal payments totaling $2.7 million from pharmaceutical companies between 2016 and 2020. Median five-year payments were $89,955 for CPGHD authors, while $521 for board-certified neurologists. The CPGHD chairperson and vice chairperson received substantial payments during the guideline development period. Nevertheless, because of less rigorous and transparent COI policy compared to international standard policies, only 10 authors disclosed their financial relationships with the pharmaceutical companies in the guideline. More than 98% of CPGHD authors received much higher personal payments from pharmaceutical companies than those to board-certified neurologists during the guideline development period in Japan.
Sections du résumé
BACKGROUND
BACKGROUND
Financial relationships between clinical guideline authors and pharmaceutical companies introduce conflicts of interest (COI), potentially biasing guideline recommendations. Thus, proper management of COI is paramount for clinical guideline authors. Nevertheless, little is known about COI among neurology clinical guideline authors. This study aimed to evaluate the financial relationships between pharmaceutical companies and authors of Clinical Practice Guideline for Headache Disorders (CPGHD) in Japan.
METHODS
METHODS
This is a retrospective analysis of 2016-2020 personal payments data disclosed by all pharmaceutical companies affiliated with the Japan Pharmaceutical Manufacturers Association. We examined amounts and fraction of personal payments to all 57 CPGHD authors and all neurologists board-certified by the Japanese Society of Neurology. Payment data was descriptively analyzed at individual author level.
RESULTS
RESULTS
Among 57 CPGHD authors, 56 (98.3%) received personal payments totaling $2.7 million from pharmaceutical companies between 2016 and 2020. Median five-year payments were $89,955 for CPGHD authors, while $521 for board-certified neurologists. The CPGHD chairperson and vice chairperson received substantial payments during the guideline development period. Nevertheless, because of less rigorous and transparent COI policy compared to international standard policies, only 10 authors disclosed their financial relationships with the pharmaceutical companies in the guideline.
CONCLUSIONS
CONCLUSIONS
More than 98% of CPGHD authors received much higher personal payments from pharmaceutical companies than those to board-certified neurologists during the guideline development period in Japan.
Identifiants
pubmed: 39472840
doi: 10.1186/s12910-024-01126-9
pii: 10.1186/s12910-024-01126-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
121Informations de copyright
© 2024. The Author(s).
Références
Schunemann HJ, Al-Ansary LA, Forland F, Kersten S, Komulainen J, Kopp IB, et al. Guidelines International Network: principles for Disclosure of interests and management of conflicts in guidelines. Ann Intern Med. 2015;163(7):548–53. https://doi.org/10.7326/M14-1885 .
doi: 10.7326/M14-1885
Institute of Medicine. Clinical Practice Guidelines We Can Trust. Washington, DC: National Academies; 2011.
Murayama A, Kamamoto S, Murata N, Yamasaki R, Yamada K, Yamashita E, et al. Evaluation of financial conflicts of interest and quality of evidence in Japanese gastroenterology clinical practice guidelines. J Gastroenterol Hepatol. 2023;38(4):565–73. https://doi.org/10.1111/jgh.16089 .
doi: 10.1111/jgh.16089
Mamada H, Murayama A, Kamamoto S, Kaneda Y, Yoshida M, Sugiura S, et al. Evaluation of Financial and Nonfinancial Conflicts of Interest and Quality of Evidence Underlying Psoriatic Arthritis Clinical Practice Guidelines: Analysis of Personal Payments From Pharmaceutical Companies and Authors’ Self-Citation Rate in Japan and the United States. Arthritis Care Res (Hoboken). 2023;75(6):1278–86. https://doi.org/10.1002/acr.25032 .
doi: 10.1002/acr.25032
Murayama A, Yamada K, Yoshida M, Kaneda Y, Saito H, Sawano T, et al. Evaluation of Conflicts of Interest among Participants of the Japanese Nephrology Clinical Practice Guideline. Clin J Am Soc Nephrol. 2022;17(6):819–26. https://doi.org/10.2215/CJN.14661121 .
doi: 10.2215/CJN.14661121
Kida F, Murayama A, Saito H, Ozaki A, Shimada Y, Tanimoto T. Pharmaceutical company payments to authors of the Japanese Clinical Practice Guidelines for Hepatitis C treatment. Liver Int. 2021;41(3):464–9. https://doi.org/10.1111/liv.14761 .
doi: 10.1111/liv.14761
Harada K, Ozaki A, Saito H, Sawano T, Yamamoto K, Murayama A, et al. Financial payments made by pharmaceutical companies to the authors of Japanese hematology clinical practice guidelines between 2016 and 2017. Health Policy. 2021;125(3):320–6. https://doi.org/10.1016/j.healthpol.2020.12.005 .
doi: 10.1016/j.healthpol.2020.12.005
Moynihan R, Lai A, Jarvis H, Duggan G, Goodrick S, Beller E, Bero L. Undisclosed financial ties between guideline writers and pharmaceutical companies: a cross-sectional study across 10 disease categories. BMJ Open. 2019;9(2):e025864. https://doi.org/10.1136/bmjopen-2018-025864 .
doi: 10.1136/bmjopen-2018-025864
Tabatabavakili S, Khan R, Scaffidi MA, Gimpaya N, Lightfoot D, Grover SC. Financial Conflicts of Interest in Clinical Practice Guidelines: A Systematic Review. Mayo Clin Proc Innov Qual Outcomes. 2021;5(2):466–75. https://doi.org/10.1016/j.mayocpiqo.2020.09.016 .
doi: 10.1016/j.mayocpiqo.2020.09.016
Steinbrook R. Guidance for guidelines. N Engl J Med. 2007;356(4):331–3. https://doi.org/10.1056/NEJMp068282 .
doi: 10.1056/NEJMp068282
Lenzer J, Hoffman JR, Furberg CD, Ioannidis JP, Guideline Panel Review Working G. Ensuring the integrity of clinical practice guidelines: a tool for protecting patients. BMJ. 2013;347:f5535. https://doi.org/10.1136/bmj.f5535 .
doi: 10.1136/bmj.f5535
Brems JH, Davis AE, Clayton EW. Analysis of conflict of interest policies among organizations producing clinical practice guidelines. PLoS ONE. 2021;16(4):e0249267. https://doi.org/10.1371/journal.pone.0249267 .
doi: 10.1371/journal.pone.0249267
Ngo-Metzger Q, Moyer V, Grossman D, Ebell M, Woo M, Miller T, et al. Conflicts of Interest in Clinical Guidelines: Update of U.S. Preventive Services Task Force Policies and Procedures. Am J Prev Med. 2018;54(1S1):S70–80. https://doi.org/10.1016/j.amepre.2017.06.034 .
doi: 10.1016/j.amepre.2017.06.034
Norris SL, Holmer HK, Burda BU, Ogden LA, Fu R. Conflict of interest policies for organizations producing a large number of clinical practice guidelines. PLoS ONE. 2012;7(5):e37413. https://doi.org/10.1371/journal.pone.0037413 .
doi: 10.1371/journal.pone.0037413
Ahlawat A, Narayanaswami P. Financial relationships between neurologists and industry: The 2015 Open Payments database. Neurology. 2019;92(21):1006–13. https://doi.org/10.1212/wnl.0000000000007640 .
doi: 10.1212/wnl.0000000000007640
Messé SR, Smith EE, Getchius TSD, Gronseth GS. American Academy of Neurology replies to Jeanne Lenzer. BMJ: Br Med J. 2013;347:f5324. https://doi.org/10.1136/bmj.f5324 .
doi: 10.1136/bmj.f5324
Nalleballe K, Sheng S, Li C, Mahashabde R, Annapureddy AR, Mudassar K, et al. Stroke. 2020;51(4):1339–43. https://doi.org/10.1161/strokeaha.119.027967 . Industry Payment to Vascular Neurologists: A 6-Year Analysis of the Open Payments Program From 2013 Through 2018.
Robbins NM, Meyer MJ, Bernat JL. Scope and nature of financial conflicts of interest between neurologists and industry: 2013–2016. Neurology. 2019;93(10):438–49. https://doi.org/10.1212/wnl.0000000000008067 .
doi: 10.1212/wnl.0000000000008067
Nguyen JL, Munshi K, Peasah SK, Swart ECS, Kohli M, Henderson R, Good CB. Trends in utilization and costs of migraine medications, 2017–2020. J Headache Pain. 2022;23(1):111. https://doi.org/10.1186/s10194-022-01476-y .
doi: 10.1186/s10194-022-01476-y
Headache Clinical Practice Guideline Development Committee. Clinical Practice Guideline for Headache Disorders 2021. Igaku-Shoin; 2021.
Murayama A, Hoshi M, Saito H, Kamamoto S, Tanaka M, Kawashima M, et al. Nature and Trends in Personal Payments Made to the Respiratory Physicians by Pharmaceutical Companies in Japan between 2016 and 2019. Respiration. 2022;101(12):1088–98. https://doi.org/10.1159/000526576 .
doi: 10.1159/000526576
Murayama A, Kamamoto S, Saito H, Yamada K, Bhandari D, Shoji I, et al. Pharmaceutical Payments to Japanese Board-Certified Infectious Disease Specialists: A Four-Year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019. Int J Environ Res Public Health. 2022;19(12):7417. https://doi.org/10.3390/ijerph19127417 .
Murayama A, Kamamoto S, Saito H, Yamashita E, Suzuki Y, Tanimoto T et al. Characteristics and Distribution of Scholarship Donations From Pharmaceutical Companies to Japanese Healthcare Institutions in 2017: A Cross-sectional Analysis. International Journal of Health Policy and Management. 2023;12(1). ARTN 7621. https://doi.org/10.34172/ijhpm.2023.7621 .
Medical Governance Research Institute. Yen For Docs. 2023. https://yenfordocs.jp/ . Accessed March 6, 2024 2024.
Ministry of Education, Culture, Sports, Science and Technology, Ministry of Health, Labour and Welfare, Ministry of Economy, Trade and Industry. Ethical Guidelines for Medical and Health Research Involving Human Subjects. Ministry of Health, Labour and Welfare, Online. 2021. https://www.mhlw.go.jp/content/000769923.pdf . Accessed August 29 2021.
Eli Lilly Japan, Japanese Headache Society. Migraine Disease Education Program approved by the Japanese Headache Society. Clinical Practice Guideline for Headache Disorders 2021. Eli Lilly Japan. 2021. https://www.lillymedical.jp/ja-jp/medical-education/neuroscience/headache-disorders/headache-practice . Accessed October 19 2023.
Combs TR, Scott J, Jorski A, Heavener T, Vassar M. Evaluation of Industry Relationships Among Authors of Clinical Practice Guidelines in Gastroenterology. JAMA Intern Med. 2018;178(12):1711–2. https://doi.org/10.1001/jamainternmed.2018.4730 .
doi: 10.1001/jamainternmed.2018.4730
Carlisle A, Bowers A, Wayant C, Meyer C, Vassar M. Financial Conflicts of Interest Among Authors of Urology Clinical Practice Guidelines. Eur Urol. 2018;74(3):348–54. https://doi.org/10.1016/j.eururo.2018.04.023 .
doi: 10.1016/j.eururo.2018.04.023
Shigeta H, Murayama A, Kamamoto S, Saito H, Ozaki A. Evaluation of Financial Conflicts of Interest and Quality of Evidence Underlying the American Diabetes Association Clinical Practice Guidelines: The Standards of Medical Care in Diabetes, 2021. Cureus. 2023;15(3):e36567. https://doi.org/10.7759/cureus.36567 .
doi: 10.7759/cureus.36567
Elder K, Turner KA, Cosgrove L, Lexchin J, Shnier A, Moore A, et al. Reporting of financial conflicts of interest by Canadian clinical practice guideline producers: a descriptive study. CMAJ. 2020;192(23):E617–25. https://doi.org/10.1503/cmaj.191737 .
doi: 10.1503/cmaj.191737
Tarras ES, Marshall DC, Rosenzweig K, Korenstein D, Chimonas S. Trends in Industry Payments to Medical Oncologists in the United States Since the Inception of the Open Payments Program, 2014 to 2019. JAMA Oncol. 2021;7(3):440–4. https://doi.org/10.1001/jamaoncol.2020.6591 .
doi: 10.1001/jamaoncol.2020.6591
Marshall DC, Tarras ES, Rosenzweig K, Korenstein D, Chimonas S. Trends in Industry Payments to Physicians in the United States From 2014 to 2018. JAMA. 2020;324(17):1785–8. https://doi.org/10.1001/jama.2020.11413 .
doi: 10.1001/jama.2020.11413
Murayama A, Kugo H, Saito Y, Saito H, Tanimoto T, Ozaki A. A 9-Year Investigation of Healthcare Industry Payments to Pulmonologists in the United States. Ann Am Thorac Soc. 2023;20(9):1283–92. https://doi.org/10.1513/AnnalsATS.202209-827OC .
doi: 10.1513/AnnalsATS.202209-827OC
Murayama A. Nine-Year Analysis of Industry Payments to Geriatricians in the United States Between 2014 and 2022. J Am Med Dir Assoc. 2023. https://doi.org/10.1016/j.jamda.2023.09.025 .
doi: 10.1016/j.jamda.2023.09.025
Murayama A. Industry Payments to Pediatricians in the United States Between 2013 and 2021. Clin Pediatr (Phila). 2023;99228231218850. https://doi.org/10.1177/00099228231218850 .
Department of Justice. Three Florida Men Charged in $46 Million Health Care Fraud, Kickback, and Money Laundering Conspiracy. 2021. https://www.justice.gov/opa/pr/three-florida-men-charged-46-million-health-care-fraud-kickback-and-money-laundering . Accessed May 20 2024.
Department of Justice. French Medical Device Manufacturer to Pay $2 Million to Resolve Alleged Kickbacks to Physicians and Related Medicare Open Payments Program Violations. 2021. https://www.justice.gov/usao-edpa/pr/french-medical-device-manufacturer-pay-2-million-resolve-alleged-kickbacks-physicians . Accessed May 14 2024.
Department of Justice. Neurosurgeon and Two Affiliated Companies Agree to Pay $4.4 Million to Settle Health Care Fraud Allegations. 2021. https://www.justice.gov/opa/pr/neurosurgeon-and-two-affiliated-companies-agree-pay-44-million-settle-health-care-fraud . Accessed March 14 2024.
Department of Justice. Medtronic to Pay Over $9.2 Million To Settle Allegations of Improper Payments to South Dakota Neurosurgeon. 2020. https://www.justice.gov/opa/pr/medtronic-pay-over-92-million-settle-allegations-improper-payments-south-dakota-neurosurgeon . Accessed May 14 2024.
Department of Health and Human Services. Fiscal Year 2020 Annual Report to Congress on the Open Payments Program. 2021. https://www.cms.gov/files/document/open-payments-2020-annual-report-congress.pdf . Accessed May 14 2024.
Department of Health and Human Services. Fiscal Year 2021 Annual Report to Congress on the Open Payments Program. 2022. https://www.cms.gov/files/document/open-payments-fy-2021-annual-report-congress.pdf . Accessed May 13 2024.
Murayama A, Shin N, Higuchi K, Kohli I, Kugo H, Senoo Y. Financial conflicts of interest between infectious diseases clinical practice guideline authors and the pharmaceutical industry in Japan. Infect Dis (Lond). 2024;1–5. https://doi.org/10.1080/23744235.2024.2309351 .
Murayama A. Financial conflicts of interest among authors of clinical practice guidelines for diabetes mellitus in Japan. J Diabetes. 2024;16(4):e13533. https://doi.org/10.1111/1753-0407.13533 .
doi: 10.1111/1753-0407.13533
Murayama A, Kamamoto S, Shigeta H, Saito H, Yamashita E, Tanimoto T, Akihiko O. Undisclosed financial conflicts of interest with pharmaceutical companies among the authors of the Esophageal Cancer Practice Guidelines 2017 by the Japan Esophageal Society. Dis Esophagus. 2022;35(10). https://doi.org/10.1093/dote/doac056 .
Murayama A, Ozaki A, Saito H, Sawano T, Shimada Y, Yamamoto K, et al. Pharmaceutical company payments to dermatology Clinical Practice Guideline authors in Japan. PLoS ONE. 2020;15(10):e0239610. https://doi.org/10.1371/journal.pone.0239610 .
doi: 10.1371/journal.pone.0239610
Yamamoto K, Murayama A, Ozaki A, Saito H, Sawano T, Tanimoto T. Financial conflicts of interest between pharmaceutical companies and the authors of urology clinical practice guidelines in Japan. Int Urogynecol J. 2021;32(2):443–51. https://doi.org/10.1007/s00192-020-04547-3 .
doi: 10.1007/s00192-020-04547-3
Murayama A, Kida F, Ozaki A, Saito H, Sawano T, Tanimoto T. Financial and Intellectual Conflicts of Interest Among Japanese Clinical Practice Guidelines Authors for Allergic Rhinitis. Otolaryngol Head Neck Surg. 2022;166(5):869–76. https://doi.org/10.1177/01945998211034724 .
doi: 10.1177/01945998211034724
Murayama A, Miyazawa K, Kamamoto S, Shigeta H, Kugo H, Higuchi K, Senoo Y. Financial conflicts of interest in Japanese obstetrics and gynaecology clinical practice guidelines. Clin Translational Discovery. 2024;4(1):e273. https://doi.org/10.1002/ctd2.273 .
doi: 10.1002/ctd2.273
Murayama A. Financial Conflicts of Interest Among the Authors of the Clinical Practice Guidelines for Rheumatoid Arthritis in Japan. Cureus. 2023;15(10):e46650. https://doi.org/10.7759/cureus.46650 .
doi: 10.7759/cureus.46650
Saito H, Ozaki A, Sawano T, Shimada Y, Tanimoto T. Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan. JAMA Netw Open. 2019;2(4):e192834. https://doi.org/10.1001/jamanetworkopen.2019.2834 .
doi: 10.1001/jamanetworkopen.2019.2834
Murayama A, Higuchi K, Kugo H. Cross-sectional analysis of pharmaceutical industry payments to board-certified breast cancer specialists in Japan. Clin Translational Discovery. 2024;4(4):e331. https://doi.org/10.1002/ctd2.331 .
doi: 10.1002/ctd2.331
Senoo Y, Saito H, Ozaki A, Sawano T, Shimada Y, Yamamoto K, et al. Pharmaceutical company payments to authors of the Japanese guidelines for the management of hypertension. Med (Baltim). 2021;100(12):e24816. https://doi.org/10.1097/MD.0000000000024816 .
doi: 10.1097/MD.0000000000024816
Murayama A, Aizawa M, Byreddy KR, Higuchi K, Senoo Y. Conflicts of Interest Among Cardiology Clinical Practice Guideline Authors in Japan. J Am Heart Assoc. 2024;13(8):e034506. https://doi.org/10.1161/jaha.124.034506 .
doi: 10.1161/jaha.124.034506
Hashimoto T, Murayama A, Mamada H, Saito H, Tanimoto T, Ozaki A. Evaluation of financial conflicts of interest and drug statements in the coronavirus disease 2019 clinical practice guideline in Japan. Clin Microbiol Infect. 2022;28(3):460–2. https://doi.org/10.1016/j.cmi.2021.11.019 .
doi: 10.1016/j.cmi.2021.11.019
Kamamoto S, Ozaki A, Murayama A. Assessment of Financial Relationships Between Otorhinolaryngologists and Pharmaceutical Companies in Japan Between 2016 and 2019. Cureus. 2023;15(8):e43633. https://doi.org/10.7759/cureus.43633 .
doi: 10.7759/cureus.43633
Murayama A. Financial Conflicts of Interest Among the Authors of the Clinical Practice Guidelines for Rheumatoid Arthritis in Japan. Cureus. 2023;15(10).
Scher JU, Schett G. Key opinion leaders - a critical perspective. Nat Rev Rheumatol. 2021;17(2):119–24. https://doi.org/10.1038/s41584-020-00539-1 .
doi: 10.1038/s41584-020-00539-1
American Urological Association. Disclosure of Conflicts of Interest Principles, Policies & Procedures for Managing Conflicts of Interest. American Urological Association, American Urological Association., 2021. https://www.auanet.org/education/auauniversity/course-planning-disclosures-and-cme/disclosures/aua-disclosure-policy . Accessed January 29 2022.
Mitchell AP, Trivedi NU, Gennarelli RL, Chimonas S, Tabatabai SM, Goldberg J, et al. Are Financial Payments From the Pharmaceutical Industry Associated With Physician Prescribing? A Systematic Review. Ann Intern Med. 2021;174(3):353–61. https://doi.org/10.7326/M20-5665 .
doi: 10.7326/M20-5665
Taheri C, Kirubarajan A, Li XL, Lam ACL, Taheri S, Olivieri NF. Discrepancies in self-reported financial conflicts of interest disclosures by physicians: a systematic review. Bmj Open. 2021;11(4):e045306. ARTN e045306. https://doi.org/10.1136/bmjopen-2020-045306 .
doi: 10.1136/bmjopen-2020-045306
Mulinari S, Ozieranski P. Capitalizing on transparency: Commercial surveillance and pharmaceutical marketing after the Physician Sunshine Act. Big Data Soc. 2022;9(1):20539517211069631. https://doi.org/10.1177/20539517211069631 .
doi: 10.1177/20539517211069631
Ozieranski P, Saito H, Rickard E, Mulinari S, Ozaki A. International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency. Global Health. 2023;19(1):14. https://doi.org/10.1186/s12992-022-00902-9 .
doi: 10.1186/s12992-022-00902-9
Murayama A, Senoo Y. Financial conflicts of interest among authors of clinical practice guideline for headache disorders and board-certified neurologists in Japan. Res Square preprint. 2023. https://doi.org/10.21203/rs.3.rs-3471270/v1 .
doi: 10.21203/rs.3.rs-3471270/v1